Abstract 2460
Background
The main purpose of the work was to study the key exosomal factors involved in the development of hormonal resistance of breast cancer cells. The work is based on our previous data, which demonstrated the effect of exosome-mediated transferring of hormonal resistance in in vitro cultured MCF-7 breast cancer cells.
Methods
Estrogen-dependent breast cancer cells MCF-7 and the tamoxifen-resistant subline MCF-7 /T were used as an experimental model. The analysis of exosomal microRNAs was performed by HiSeq2500 and at least 5 million reads per samples were obtained. MicroRNA was extracted from by PureLink RNA Micro Kit; library preparation was carried out with NEBNext® Small RNA Library Prep Set for Illumina®. Transfection of the RNA oligonucleotides was performed using Metafectene PRO (Biontex) to result in the final RNA concentration of 50 nM.
Results
A comparative analysis of exosomal miRNAs of MCF-7 and resistant MCF-7/T cells was carried out. In total, 2588 miRNAs have been identified in the exosomes. Among them, mir-181 family, which is one of the negative regulators of estrogen-dependent growth, was identified as the group of miRs, hyperexpressed in the resistant exosomes. Following this, we analysed the role of mir-181c, one of the main members of miR-181 family, in the regulation of cell growth and hormonal response. Mir-181c transfection was found to induce the estrogen-independent growth and partial tamoxifen resistance of MCF-7 cells. The study of the signaling proteins showed that mir-181c transfection, in contrast to scrambled RNA transfection, caused the increase of the amount of Raptor, phosphorylated forms of mTOR and Akt that correlated with increased AP-1 transcriptional activity.
Conclusions
We have demonstrated the involvement of miR-181c in the development of hormonal resistance of breast cancer cells that allows us to consider mir-181 as the perspective target of the treatment of hormone- independent cancers. The research was supported by the Russian Science Foundation (19-15-00245, miRNA analysis) and RFBR (#18-29-09017, tamoxifen resistance).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation, project 19-15-00245.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract